Page 99 - Read Online

Page 16 of 18 Stuivenberg et al. Microbiome Res Rep 2025;4:11 https://dx.doi.org/10.20517/mrr.2024.22

38. Cosola C, Rocchetti MT, di Bari I, et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine
permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins
2021;13:334. DOI PubMed PMC
39. Guida B, Germanò R, Trio R, et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal
failure: a randomized clinical trial. Nutr Metab Cardiovasc Dis 2014;24:1043-9. DOI
40. Rossi M, Johnson DW, Morrison M, et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized
trial. Clin J Am Soc Nephrol 2016;11:223-31. DOI PubMed PMC
41. Natarajan R, Pechenyak B, Vyas U, et al. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis
patients. Biomed Res Int 2014;2014:568571. DOI PubMed PMC
42. de Faria Barros A, Borges NA, Nakao LS, et al. Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins
in non-dialysis chronic kidney patients: a double-blind, randomized, placebo-controlled trial. J Funct Foods 2018;46:378-83. DOI
43. Pavan M. Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease. Minerva Urol Nefrol
2016;68:222-6. PubMed
44. De Mauri A, Carrera D, Bagnati M, et al. Probiotics-supplemented low-protein diet for microbiota modulation in patients with
advanced chronic kidney disease (ProLowCKD): results from a placebo-controlled randomized trial. Nutrients 2022;14:1637. DOI
PubMed PMC
45. Poesen R, Evenepoel P, de Loor H, et al. The influence of prebiotic arabinoxylan oligosaccharides on microbiota derived uremic
retention solutes in patients with chronic kidney disease: a randomized controlled trial. PLoS One 2016;11:e0153893. DOI PubMed
PMC
46. Ranganathan N, Patel B, Ranganathan P, et al. Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats.
ScientificWorldJournal 2005;5:652-60. DOI PubMed PMC
47. Nakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients:
a preliminary study. Nephrol Dial Transplant 2011;26:1094-8. DOI
48. Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients
on hemodialysis. Am J Kidney Dis 2003;41:S142-5. DOI PubMed
49. Andrade-Oliveira V, Amano MT, Correa-Costa M, et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am
Soc Nephrol 2015;26:1877-88. DOI PubMed PMC
50. Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in
hemodialysis patients. J Ren Nutr 2005;15:77-80. DOI
51. Ando Y, Miyata Y, Tanba K, et al. [Effect of oral intake of an enteric capsule preparation containing Bifidobacterium longum on the
progression of chronic renal failure]. Nihon Jinzo Gakkai Shi 2003;45:759-64. PubMed
52. Iwashita Y, Ohya M, Yashiro M, et al. Dietary changes involving Bifidobacterium longum and other nutrients delays chronic kidney
disease progression. Am J Nephrol 2018;47:325-32. DOI PubMed
53. Stuivenberg GA, Chmiel JA, Akouris PP, et al. Supplementing yogurt with probiotic Bifidobacteria to counter chronic kidney
disease. Fermentation 2023;9:391. DOI
54. Yamaguchi J, Tanaka T, Inagi R. Effect of AST-120 in chronic kidney disease treatment: still a controversy? Nephron 2017;135:201-
6. DOI
55. Schulman G, Vanholder R, Niwa T. AST-120 for the management of progression of chronic kidney disease. Int J Nephrol Renovasc
Dis 2014;7:49-56. DOI PubMed PMC
56. Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Ohta H. Gender difference of association between LDL cholesterol concentrations and
mortality from coronary heart disease amongst Japanese: the Ibaraki Prefectural Health Study. J Intern Med 2010;267:576-87. DOI
PubMed
57. Imamura T, Doi Y, Arima H, et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general
Japanese population: the Hisayama study. Stroke 2009;40:382-8. DOI
58. Tanabe N, Iso H, Okada K, et al; Japan Arteriosclerosis Longitudinal Study Group. Serum total and non-high-density lipoprotein
cholesterol and the risk prediction of cardiovascular events - the JALS-ECC -. Circ J 2010;74:1346-56. DOI PubMed
59. Sugiyama D, Okamura T, Watanabe M, et al; NIPPON DATA 80/90 Research Group. Risk of hypercholesterolemia for
cardiovascular disease and the population attributable fraction in a 24-year Japanese cohort study. J Atheroscler Thromb 2015;22:95-
107. DOI
60. Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.
Hepatology 2014;60:679-86. DOI PubMed PMC
61. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005;46:1225-8. DOI
PubMed
62. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013;127:96-103. DOI PubMed
PMC
63. Michael DR, Davies TS, Moss JWE, et al. The anti-cholesterolaemic effect of a consortium of probiotics: an acute study in C57BL/6J
mice. Sci Rep 2017;7:2883. DOI PubMed PMC
64. Ivey KL, Hodgson JM, Kerr DA, Thompson PL, Stojceski B, Prince RL. The effect of yoghurt and its probiotics on blood pressure
and serum lipid profile; a randomised controlled trial. Nutr Metab Cardiovasc Dis 2015;25:46-51. DOI PubMed